香港股市 將在 3 小時 11 分鐘 開市

Astellas Pharma Inc. (ALPMY)

OTC Markets OTCPK - OTC Markets OTCPK 延遲價格。貨幣為 USD。
加入追蹤清單
9.99+0.13 (+1.32%)
收市:04:00PM EDT

Astellas Pharma Inc.

2-5-1, Nihonbashi-Honcho
Chuo-Ku
Tokyo 103-8411
Japan
81 3 3244 3000
https://www.astellas.com

版塊Healthcare
行業Drug Manufacturers—General
全職員工

高階主管

名稱頭銜支付行使價出生年份
Mr. Naoki Okamura BScPresident, CEO & Director930.17k1962
Mr. Atsushi KitamuraChief Financial Officer
Nobue YasudaGeneral Manager of Finance & Accounting Department
Mr. Yoshitsugu Shitaka Ph.D.Chief Scientific Officer & Senior Managing Executive Officer
Ms. Catherine B. LevittGeneral Counsel
Mr. Katsuyoshi SugitaChief People Officer, Chief Ethics & Compliance Officer, EVP of HR and Representative Director1967
Mr. Stig OgataVice President of Corporate Communications
Ms. Collette TaylorSenior Vice President of Human Resources1963
Ms. Tatjana DragovicSenior VP and Head of Ethics & Compliance
Mr. Nobuaki TanakaPresident of Japan Commercial & Senior Corporate Executive
截止 2023年12月31日為止計算的金額,現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants. Th company has a research collaboration with Vivtex Corporation to evaluate Vivtex's GI-ORIS screening and formulation platform technology to support the development of novel and oral versions of a therapeutic candidate provided by Astellas; and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize integrated diabetes self-management solution. The company was founded in 1923 and is headquartered in Tokyo, Japan.

公司管治

截至 2024年5月1日 止,Astellas Pharma Inc. 的 ISS 管治質素評分為 2。 Pillar 分數正在審核中:1;董事會:2;股東權利:6;現金賠償:1。

企業管治評分的資料提供: Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險,而 10 分表示較高的管治風險。